Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representation

A breakthrough in oncology research was the discovery of doxorubicin (Dox) in the 1960's. Unlike other chemotherapy drugs, Dox was determined to have a greater therapeutic index. Since its discovery, Dox has, in part, contributed to the 5-10-year survival increase in cancer patient outcomes. Unfortunately, despite its efficacy, both in adult and pediatric cancers, the clinical significance of Dox is tainted by its adverse side effects, which usually manifest as cardiotoxicity. The issue stems from Dox's lack of specificity which prevents it from accurately distinguishing between cancer cells and healthy cell lines, like cardiomyocytes. In addition, the high binding affinity of Dox to topoisomerases, which are abundantly found in cancer and cardiac cells in different isoforms, potentiates DNA damage. In both cell lines, Dox induces cytotoxicity by stimulating the production of pro-oxidants whilst inhibiting antioxidant enzymatic activity. Given that the cardiac muscle has an inherently low antioxidant capacity makes it susceptible to oxidative damage thereby, allowing the accumulation of Dox within the myocardium. Subsequently, Dox drives the activation of cell death pathways, such as ferroptosis, necroptosis and apoptosis by triggering numerous cellular responses that have been implicated in diseases. To date, the exact mechanism by which Dox induces the cardiotoxicity remains an aspect of much interest in cardio-oncology research. Hence, the current review summarizes the proposed mechanisms that are associated with the onset and progression of DIC.

Automated summary

A breakthrough in oncology research was the discovery of doxorubicin (Dox), a chemotherapy drug with a higher therapeutic index. However, its clinical significance is tainted by its adverse side effects, particularly cardiotoxicity, due to its lack of specificity in distinguishing cancer cells from healthy cells. Dox induces cytotoxicity by stimulating the production of pro-oxidants and inhibiting antioxidant enzymatic activity in both cancer and cardiac cells. The low antioxidant capacity of cardiac muscle makes it susceptible to oxidative damage and triggers cell death pathways.